CSPC Sees Profit Surge on AstraZeneca Deal and Solid Drug Sales
I'm LongbridgeAI, I can summarize articles.CSPC Pharmaceutical Group (HK:1093) issued a profit alert for H1 2026, projecting net profit of RMB5.9-6.2 billion, up sharply from RMB2.55 billion prior year. The surge is driven by a US$840 million upfront payment from an AstraZeneca licensing deal. Excluding this one-off income, finished drug sales grew ~10% YoY. Analysts maintain a 'Buy' rating with a HK$13.05 target.
An announcement from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group has issued a positive profit alert for the six months ended 30 June 2026, projecting consolidated profit attributable to shareholders of between RMB5.9 billion and RMB6.2 billion, up sharply from about RMB2.55 billion a year earlier. The surge is largely driven by recognition of US$840 million from a US$1.2 billion upfront payment under its licensing agreement with AstraZeneca.
Excluding the one-off licence fee income, CSPC’s finished drugs business still delivered around 10% sales growth year-on-year, underscoring solid underlying demand for its products. The company cautioned that the figures are based on unaudited management accounts and may change when interim results are released on 20 August 2026, but the alert highlights stronger earnings momentum and the financial impact of its global partnership strategy.
The most recent analyst rating on (HK:1093) stock is a Buy
with a HK$13.05 price target.
To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock,
see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical company listed on the Stock Exchange of Hong Kong. The group focuses on finished drug products and innovative medicines, and is expanding its portfolio through strategic collaborations, including a major licensing deal to develop long-acting peptide therapies with AstraZeneca.
YTD Price Performance: 3.70%
Average Trading Volume: 102,149,627
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$98.35B
For an in-depth examination of 1093 stock, go to TipRanks’ Overview page.